Impact Factor 3.258 | CiteScore 2.7
More on impact ›

Correction ARTICLE

Front. Genet., 28 July 2020 | https://doi.org/10.3389/fgene.2020.00690

Corrigendum: Bradykinin-Mediated Angioedema: An Update of the Genetic Causes and the Impact of Genomics

Itahisa Marcelino-Rodriguez1, Ariel Callero2, Alejandro Mendoza-Alvarez1, Eva Perez-Rodriguez2, Javier Barrios-Recio2, Jose C. Garcia-Robaina2 and Carlos Flores1,3,4,5*
  • 1Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Universidad de La Laguna, Santa Cruz de Tenerife, Spain
  • 2Allergy Unit, Hospital Universitario Nuestra Señora de Candelaria, Universidad de La Laguna, Santa Cruz de Tenerife, Spain
  • 3Instituto Tecnológico y de Energías Renovables (ITER), Genomics Division, Santa Cruz de Tenerife, Spain
  • 4CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
  • 5Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, Santa Cruz de Tenerife, Spain

A Corrigendum on
Bradykinin-Mediated Angioedema: An Update of the Genetic Causes and the Impact of Genomics

by Marcelino-Rodriguez, I., Callero, A., Mendoza-Alvarez, A., Perez-Rodriguez, E., Barrios-Recio, J., Garcia-Robaina, J. C., et al. (2019). Front. Genet. 10:900. doi: 10.3389/fgene.2019.00900

In the original article, there was a mistake in Table 1 as published. The study conducted by Veronez et al. (2018) did not focus on acquired forms of angioedema (AAE). In addition, the study published in 2017 by the same author, describes a rare mutation detected within F12 gene in a patient with angioedema induced by angiotensin-converting enzyme inhibitors. The reference (Veronez et al., 2018) has been modified to Veronez et al. (2017). Besides, one of the gene acronyms “BDKRB2” was not set in italics. This is has been corrected and shown in Table 1 below.

TABLE 1
www.frontiersin.org

Table 1. Genetic studies of acquired bradykinin-mediated angioedema (Bk-AE) published until 2018.

Also, we stated that in the study conducted by Dewald (2018) there is another rare variant affecting function detected within PLG gene. However, this is the same variant (p.Lys330Glu) described by Bork et al. (2018). This error was caused by the use of different nomenclature, where Bork et al., uses the correct nomenclature indicated by the Human Genome Variation Society guidelines. At the moment, only one PLG causal variant affecting function is reported in the scientific literature. A correction has been made to the third paragraph of Section: NGS to Fully Define HAE Genetics:

Another recent WES study in families with HAE-nC1-INH with unknown genetic causes identified the plasminogen gene (PLG) as a new causal gene (Bork et al., 2018). In this case, a p.Lys330Glu variant located in exon 9 was found in 14 German patients while it was absent from gnomAD. This variant predicted a change in the kringle 3 domain of plasminogen. The variant was found in all symptomatic patients and in nine out of 38 index patients from other independent families. In fact, two other studies identified the same variant in HAE cases from France and Japan (Belbézier et al., 2018; Yakushiji et al., 2018). Another study screened PLG for variants in eight unrelated index patients from Germany with HAE-nC1-INH with unknown genetic causes (Dewald, 2018). They also found the rare non-conservative missense variant in exon 9 (p.Lys330Glu) in three of the patients, using isoelectric focusing of plasma samples followed by an immunoblotting procedure, this study demonstrated that the presence of the p.Lys330Glu variant was associated with the presence of an aberrant plasminogen protein.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

References

Akcali, C., Ozkur, M., Erbagci, Z., Benlier, N., and Aynacioglu, A. S. (2008). Association of insertion/deletion polymorphism of the angiotensin-converting enzyme gene with angio-oedema accompanying chronic urticaria but not chronic urticaria without angio-oedema or the autologous serum skin test response. J. Eur. Acad. Dermatol. Venereol. 22, 83–86. doi: 10.1111/j.1468-3083.2007.02353.x

CrossRef Full Text | Google Scholar

Bas, M., Hoffmann, T. K., Tiemann, B., Dao, V. T., Bantis, C., Balz, V., et al. (2010). Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema. Br. J. Clin. Pharmacol. 69, 179–186. doi: 10.1111/j.1365-2125.2009.03567.x

PubMed Abstract | CrossRef Full Text | Google Scholar

Belbézier, A., Hardy, G., Marlu, R., Defendi, F., Dumestre Perard, C., Boccon-Gibod, I., et al. (2018). Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: three additional French families. Allergy 73, 2237–2239. doi: 10.1111/all.13543

PubMed Abstract | CrossRef Full Text | Google Scholar

Bork, K., Wulff, K., Steinmüller-Magin, L., Braenne, I., Staubach-Renz, P., Witzke, G., et al. (2018). Corrigendum. Allergy 73:2412. doi: 10.1111/all.13623

CrossRef Full Text | Google Scholar

Cilia La Corte, A. L., Carter, A. M., Rice, G. I., and Duan, Q. L. (2011). A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema. Hum. Mutat. 32, 1326–1331. doi: 10.1002/humu.21579

PubMed Abstract | CrossRef Full Text | Google Scholar

Dewald, G. (2018). A missense mutation in the plasminogen gene, within the plasminogen kringle 3 domain, in hereditary angioedema with normal C1 inhibitor. Biochem. Biophys. Res. Commun. 498, 193–198. doi: 10.1016/j.bbrc.2017.12.060

PubMed Abstract | CrossRef Full Text | Google Scholar

Duan, Q. L., Nikpoor, B., Dube, M.-P., Molinaro, G., Meijer, I. A., Dion, P., et al. (2005). A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am. J. Hum. Genet. 77, 617–626.

PubMed Abstract | Google Scholar

Gulec, M., Caliskaner, Z., Tunca, Y., Ozturk, S., Bozoglu, E., Gul, D., et al. (2008). The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Allergol. Immunopathol. 36, 134–140. doi: 10.1016/S0301-0546(08)72537-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Mahmoudpour, S. H., Leusink, M., van der Putten, L., Terreehorst, I., Asselbergs, F. W., de Boer, A., et al. (2013). Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics 14, 249–260. doi: 10.2217/pgs.12.206

PubMed Abstract | CrossRef Full Text | Google Scholar

Moholisa, R. R., Rayner, B. R., Patricia Owen, E., Schwager, S. L. U., Stark, J. S., Badri, M., et al. (2013). Association of B 2 receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans. J. Clin. Hypertens. 15, 413–419. doi: 10.1111/jch.12104

PubMed Abstract | CrossRef Full Text | Google Scholar

Molinaro, G., Duan, Q. L., Chagnon, M., Moreau, M. E., Simon, P., Clavel, P., et al. (2006). Kinin-dependent hypersensitivity reactions in hemodialysis: metabolic and genetic factors. Kidney Int. 70, 1823–1831. doi: 10.1038/sj.ki.5001873

PubMed Abstract | CrossRef Full Text | Google Scholar

Osmanagaoglu, M. A., Okumuş, B., and Bozkaya, H. (2006). Skin venous thromboembolism by combined oral contraceptive in a woman with acquired angioedema and Factor V Leiden mutation. Contraception 73, 311–314. doi: 10.1016/j.contraception.2005.09.006

PubMed Abstract | CrossRef Full Text | Google Scholar

Pare, G., Kuboj, M., Byrd, J. B., McCarty, C. A., Woodard-Grice, A., Teo, K. K., et al. (2013). Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet. Genomics 23, 470–478. doi: 10.1038/jid.2014.371

PubMed Abstract | CrossRef Full Text | Google Scholar

Veronez, C. L., Moreno, A. S., Constantino-Silva, R. N., Maia, L. S. M., Ferriani, M. P. L., Castro, F. F. M., et al. (2018). Hereditary angioedema with normal C1 inhibitor and F12 mutations in 42 Brazilian families. J. Allergy Clin. Immunol. Pract. 6, 1209–1216.e8. doi: 10.1016/j.jaip.2017.09.025

PubMed Abstract | CrossRef Full Text | Google Scholar

Veronez, C. L., Serpa, F. S., and Pesquero, J. B. (2017). A rare mutation in the F12 gene in a patient with ACE inhibitor-induced angioedema. Ann. Allergy Asthma Immunol. 118, 743–745. doi: 10.1016/j.anai.2017.04.014

PubMed Abstract | CrossRef Full Text | Google Scholar

Woodard-Grice, A. V., Lucisano, A. C., Byrd, J. B., Stone, E. R., Simmons, W. H., and Brown, N. J. (2010). Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet. Genomics 20, 532–536. doi: 10.1097/FPC.0b013e32833d3acb

PubMed Abstract | CrossRef Full Text | Google Scholar

Yakushiji, H., Hashimura, C., Fukuoka, K., Kaji, A., Miyahara, H., Kaname, S., et al. (2018). A missense mutation of the plasminogen gene in hereditary angioedema with normal C1 inhibitor in Japan. Allergy 73, 2244–2247. doi: 10.1111/all.13550

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: angioedema, inheritance, diagnosis, sequencing, precision medicine

Citation: Marcelino-Rodriguez I, Callero A, Mendoza-Alvarez A, Perez-Rodriguez E, Barrios-Recio J, Garcia-Robaina JC and Flores C (2020) Corrigendum: Bradykinin-Mediated Angioedema: An Update of the Genetic Causes and the Impact of Genomics. Front. Genet. 11:690. doi: 10.3389/fgene.2020.00690

Received: 30 April 2020; Accepted: 05 June 2020;
Published: 28 July 2020.

Edited and reviewed by: Anastasios E. Germenis, University of Thessaly, Greece

Copyright © 2020 Marcelino-Rodriguez, Callero, Mendoza-Alvarez, Perez-Rodriguez, Barrios-Recio, Garcia-Robaina and Flores. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Carlos Flores, cflores@ull.edu.es